Alger S, Larson K, Boyce V L, Seagle H, Fontvieille A M, Ferraro R T, Rising R, Ravussin E
Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ 85016.
Am J Clin Nutr. 1993 Feb;57(2):120-6. doi: 10.1093/ajcn/57.2.120.
The effect of phenylpropanolamine (PPA), a noncatecholamine sympathomimetic weight-loss agent, on energy expenditure (EE) and substrate oxidation was measured in a respiratory chamber in 24 overweight women after 4 d of treatment (PPA or placebo) during weight maintenance and after 7 wk of treatment on a hypoenergetic diet (70% of measured baseline 24-h EE). Twelve women (37 +/- 2 y, 74 +/- 6 kg, 33 +/- 1% body fat) were randomly assigned to the PPA group [75 mg osmotic release oral system (OROS)-PPA/d] and 12 (mean +/- SEM: 38 +/- 2 y, 79 +/- 1 kg, 37 +/- 1% body fat) to the placebo group. Baseline measurements of 24-h EE (7849 +/- 226 vs 7834 +/- 142 kJ/d), basal metabolic rate (BMR) and 24-h respiratory quotient (RQ) were comparable between PPA and placebo groups. After 4 d of treatment, there was no significant effect of PPA on 24-h EE, BMR, and 24-h RQ compared with placebo. Over the 7-wk diet period, however, the PPA group (n = 8) had greater weight loss than the placebo group (n = 10): -5.0 +/- 0.5 vs -3.0 +/- 0.4 kg (P < 0.05). The changes in 24-h EE and 24-h RQ over the 7 wk were not different between the groups. We conclude that weight loss is enhanced by OROS-PPA, but this change was not explained by changes in 24-h EE or 24-h RQ. The small number of subjects may have hindered detection of subtle differences in energy metabolism.
苯丙醇胺（PPA）是一种非儿茶酚胺类拟交感神经减肥药，在呼吸室内对24名超重女性进行了研究，测量其在体重维持期接受4天治疗（PPA或安慰剂）后以及在低能量饮食（测量的基线24小时能量消耗的70%）治疗7周后的能量消耗（EE）和底物氧化情况。12名女性（年龄37±2岁，体重74±6千克，体脂33±1%）被随机分配到PPA组[75毫克渗透泵控释口服系统（OROS）-PPA/天]，12名女性（平均±标准误：年龄38±2岁，体重79±1千克，体脂37±1%）被分配到安慰剂组。PPA组和安慰剂组之间24小时EE（7849±226与7834±142千焦/天）、基础代谢率（BMR）和24小时呼吸商（RQ）的基线测量值具有可比性。治疗4天后，与安慰剂相比，PPA对24小时EE、BMR和24小时RQ没有显著影响。然而，在7周的饮食期内，PPA组（n = 8）的体重减轻幅度大于安慰剂组（n = 10）：-5.0±0.5与-3.0±0.4千克（P < 0.05）。两组在7周内24小时EE和24小时RQ的变化没有差异。我们得出结论，OROS-PPA可增强体重减轻，但这种变化不能用24小时EE或24小时RQ的变化来解释。受试者数量较少可能阻碍了对能量代谢细微差异的检测。
